PHYSIOLOGICALLY-BASED PHARMACOKINETIC MODELING (PBPK) OF PITAVASTATIN AND ATORVASTATIN TO PREDICT DRUG-DRUG INTERACTIONS (DDIS).

被引：0
|
作者：
Duan, P. [1 ]
Zhao, P. [2 ]
Zhang, L. [2 ]
机构：
[1] US FDA, Silver Spring, MD USA
[2] US FDA, Off Clin Pharmacol, Off Translat Sci, CDER, Silver Spring, MD USA
来源：
CLINICAL PHARMACOLOGY & THERAPEUTICS | 2015年 / 97卷
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
PT-17
引用
收藏
页码：S16 / S17
页数：2
相关论文
共 50 条
  • [1] Physiologically Based Pharmacokinetic (PBPK) Modeling of Pitavastatin and Atorvastatin to Predict Drug-Drug Interactions (DDIs)
    Duan, Peng
    Zhao, Ping
    Zhang, Lei
    [J]. EUROPEAN JOURNAL OF DRUG METABOLISM AND PHARMACOKINETICS, 2017, 42 (04) : 689 - 705
  • [2] Physiologically Based Pharmacokinetic (PBPK) Modeling of Pitavastatin and Atorvastatin to Predict Drug-Drug Interactions (DDIs)
    Peng Duan
    Ping Zhao
    Lei Zhang
    [J]. European Journal of Drug Metabolism and Pharmacokinetics, 2017, 42 : 689 - 705
  • [3] PHYSIOLOGICALLY BASED PHARMACOKINETIC (PBPK) MODELING OF ELAGOLIX FOR PREDICTION OF DRUG-DRUG INTERACTIONS (DDIS)
    Chiney, M. S.
    Polepally, A. R.
    Nader, A. M.
    Dufek, M. B.
    Klein, C. E.
    Ng, J. W.
    Shebley, M.
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2017, 101 (S1) : S59 - S59
  • [4] QUALIFICATION AND APPLICATION OF PHYSIOLOGICALLY-BASED PHARMACOKINETIC (PBPK) MODELING AND SIMULATION (MANDS) TO PREDICT DRUG-DRUG INTERACTIONS FOR ALISERTIB
    Patel, C.
    Ananthula, H.
    Zhou, X.
    Xia, C.
    Chowdhury, S.
    Zhu, A.
    Pusalkar, S.
    Venkatakrishnan, K.
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2017, 101 (S1) : S82 - S82
  • [5] Physiologically-Based Pharmacokinetic Modeling of Macitentan: Prediction of Drug-Drug Interactions
    de Kanter, Ruben
    Sidharta, Patricia N.
    Delahaye, Stphane
    Gnerre, Carmela
    Segrestaa, Jerome
    Buchmann, Stephan
    Kohl, Christopher
    Treiber, Alexander
    [J]. CLINICAL PHARMACOKINETICS, 2016, 55 (03) : 369 - 380
  • [6] PHYSIOLOGICALLY-BASED PHARMACOKINETIC MODELING OF ATORVASTATIN AND RELATED SPECIES AND PREDICTION OF DRUG-DRUG INTERACTIONS IN HUMANS.
    Morse, B. L.
    Alberts, J. J.
    Kolur, A.
    Posada, M. M.
    Tham, L.
    Loghin, C.
    Hall, S. D.
    Dickinson, G. L.
    Hillgren, K. M.
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2019, 105 : S63 - S64
  • [7] PHYSIOLOGICALLY-BASED PHARMACOKINETIC (PBPK) MODELING TO EVALUATE DRUG-DRUG INTERACTION (DDI) RISK OF ALECTINIB.
    Cleary, Y.
    Gertz, M.
    Morcos, P. N.
    Youdim, K.
    Fowler, S.
    Yu, L.
    Sekiguchi, N.
    Takanashi, K.
    Kaneko, A.
    Phipps, A.
    Parrott, N.
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2017, 101 (S1) : S40 - S40
  • [8] Physiologically based pharmacokinetic modeling of disposition and drug-drug interactions for atorvastatin and its metabolites
    Zhang, Tao
    [J]. EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2015, 77 : 216 - 229
  • [9] Physiologically-Based Pharmacokinetic Modeling to Support the Clinical Management of Drug-Drug Interactions With Bictegravir
    Stader, Felix
    Battegay, Manuel
    Marzolini, Catia
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2021, 110 (05) : 1231 - 1239
  • [10] Physiologically-based pharmacokinetic modeling to predict CYP3A4-mediated drug-drug interactions of finerenone
    Wendl, Thomas
    Frechen, Sebastian
    Gerisch, Michael
    Heinig, Roland
    Eissing, Thomas
    [J]. CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY, 2022, 11 (02): : 199 - 211
12345